AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year’s $8.7 billion bet on Cerevel Therapeutics following the failure of the deal’s key drug candidate.

The drugmaker acquired emraclidine with its $8.7 billion purchase of Cerevel Therapeutics, gaining a portfolio of drugs being tested for a range of neurological conditions. Analysts had described ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission.

North Chicago-based pharmaceutical giant AbbVie acquired the drug, called emraclidine, in an $8.7 billion acquisition of Cerevel Therapeutics last year. At the time, industry analysts predicted ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

AbbVie plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday, months after its experimental ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

Early this month, the Humira maker said that the non-cash charge reflected two failed mid-stage trials designed to evaluate Cerevel Therapeutics' lead drug, emraclidine, in schizophrenia.